The January price hike was already baked into Teva’s prior guidance for 2013 Copaxone sales (#msg-81977344), which implies about $2.9B of Copaxone sales in the US.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”